Dermatol Ther. 2004;17(5):427-31. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Patel T(1), Gordon KB. Author information:
Abstract. The next generation of targeted biologic therapies for psoriasis will either be directed against new protein targets or improve on the efficacy, safety, .
Adalimumab efficacy and safety in patients with moderate to severe chronic. Laboratories and will discuss the use of adalimumab for psoriasis, a disease for. drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: .
For scalp lesion, adalimumab showed similar efficacy to etanercept nonresponders.. that show favorable therapeutic responses in psoriasis and psoriatic arthritis (PsA).. .. Only one study has shown that patients of rheumatoid arthritis who .
This phase 3 trial evaluated the safety and efficacy of adalimumab in patients with. psoriasis or with psoriatic arthritis regardless of severity of psoriatic skin and .
Conclusion Adalimumab will be a welcomed addition to our psoriasis. Gordon K (2004) Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.